Spots Global Cancer Trial Database for gastric cancer stage iv
Every month we try and update this database with for gastric cancer stage iv cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| PD-1 Antibody in EBV Positive Metastatic Gastric Cancer Patients. | NCT03755440 | Gastric Cancer ... EBV | PD-1 antibody (... | 18 Years - | Sun Yat-sen University | |
| PD-1 Antibody in EBV Positive Metastatic Gastric Cancer Patients. | NCT03755440 | Gastric Cancer ... EBV | PD-1 antibody (... | 18 Years - | Sun Yat-sen University | |
| Intraperitoneal Paclitaxel Plus Systemic mFOLFOX6 | NCT03618758 | Gastric Cancer ... Peritoneal Carc... Intraperitoneal... mFOLFOX6 | Paclitaxel mFOLFOX6 regime... | 20 Years - 79 Years | Seoul National University Bundang Hospital | |
| Phase I/II Study of the Combination of Irinotecan and POF (POFI) and Tislelizumab | NCT05319639 | Gastric Cancer ... | Oxaliplatin Levo-Leucovorin 5-fluorouracil Paclitaxel Irinotecan Tislelizumab | 18 Years - 75 Years | Fujian Cancer Hospital | |
| Stomach Cancer Exosome-based Detection | NCT06342427 | Gastric Cancer Gastric Adenoca... Gastric Cancer ... Gastric Neoplas... Gastric Lesion Gastric Cancer ... Gastric Cancer ... Gastric Cancer ... Gastric Cancer ... Gastric Cancer ... Gastric Cancer ... Gastric Cancer,... Gastric Cancer ... Gastric Cancer ... Gastric Cancer ... Gastric Cancer ... Gastric Cancer ... Gastric Cancer ... Gastric Cancer ... | DESTINEX | 18 Years - | City of Hope Medical Center | |
| Efficacy and Safety of Sintilimab Combined Intraperitoneal and Intravenous Paclitaxel Plus Oral S-1 in Gastric Cancer Patients With Peritoneal Metastasis | NCT05204173 | Gastric Cancer ... Peritoneal Meta... | sintilimab, pac... | 18 Years - | Ruijin Hospital | |
| Maintenance Treatment With S-1 in Gastric Cancer Patients | NCT03701373 | Gastric Cancer ... Cancer of Stoma... | S-1 maintenance Observation | 18 Years - 80 Years | Sun Yat-sen University | |
| Intraperitoneal Paclitaxel Plus Systemic mFOLFOX6 | NCT03618758 | Gastric Cancer ... Peritoneal Carc... Intraperitoneal... mFOLFOX6 | Paclitaxel mFOLFOX6 regime... | 20 Years - 79 Years | Seoul National University Bundang Hospital | |
| Tislelizumab Combined With Chemotherapy in First-line Treatment of AGC | NCT06034964 | Tislelizumab Chemotherapy First-line Gastric Cancer ... | Tislelizumab | 18 Years - | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | |
| To Evaluate the Efficacy of NY-ESO-1-specific T Cell Receptor Affinity Enhancing Specific T Cell in Solid Tumors | NCT03159585 | Liver Cancer St... Gastric Cancer ... Esophageal Canc... Bone and Soft T... Breast Cancer S... Bladder Carcino... Prostate Carcin... Thyroid Cancer ... Ovarian Cancer ... Solid Tumor | TAEST16001 | 18 Years - 75 Years | Zhujiang Hospital | |
| Trastuzumab to Patients With Advanced Gastric Cancer With HER2 Positive Expression in CTC | NCT04168931 | Gastric Cancer ... | Trastuzumab | 18 Years - | AC Camargo Cancer Center | |
| Conversion Therapy of Sintilimab in Combination With Apatinib and Chemotherapy in Stage IV Gastric Cancer | NCT04267549 | Gastric Cancer ... | sintilimab apatinib S1 Nab paclitaxel | 18 Years - 75 Years | Tianjin Medical University Cancer Institute and Hospital | |
| Efficacy and Safety of Toripalimab Combined With Docetaxel or Nab-paclitaxel in Patients With Advanced Gastric Cancer | NCT04563975 | Gastric Cancer ... | Toripalimab Docetaxel nab-paclitaxel | 18 Years - 75 Years | Wuhan Union Hospital, China | |
| Phase I/II Study of the Combination of Irinotecan and POF (POFI) and Tislelizumab | NCT05319639 | Gastric Cancer ... | Oxaliplatin Levo-Leucovorin 5-fluorouracil Paclitaxel Irinotecan Tislelizumab | 18 Years - 75 Years | Fujian Cancer Hospital | |
| Maintenance Treatment With S-1 in Gastric Cancer Patients | NCT03701373 | Gastric Cancer ... Cancer of Stoma... | S-1 maintenance Observation | 18 Years - 80 Years | Sun Yat-sen University | |
| Tislelizumab Combined With Chemotherapy in First-line Treatment of AGC | NCT06034964 | Tislelizumab Chemotherapy First-line Gastric Cancer ... | Tislelizumab | 18 Years - | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | |
| Conversion Therapy of Sintilimab in Combination With Apatinib and Chemotherapy in Stage IV Gastric Cancer | NCT04267549 | Gastric Cancer ... | sintilimab apatinib S1 Nab paclitaxel | 18 Years - 75 Years | Tianjin Medical University Cancer Institute and Hospital | |
| Pembrolizumab, Olaparib, Recurrent/Advanced Gastric and Gastro-esophageal Junction(GEJ) Cancer With HRR Mutation and MSS | NCT04592211 | Gastric Cancer ... | olaparib+pembro... | 19 Years - | Yonsei University | |
| Predictive Role of Circulating Angiogenic Factors for Second-line Paclitaxel and Ramucirumab. | NCT05301465 | Gastric Cancer ... | 18 Years - | University of Pisa |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
